[USA] Cardax Inc. (“Cardax”) (OTCQB:CDXI) announced today that it initiated a single-dose pharmacokinetic study in non-human primates (monkeys) to compare the bioavailability (exposure) of CDX-085 the Company’s patented consumer health product candidate to microalgal astaxanthin the predominate astaxanthin consumer health form on the market.
Results are anticipated in July and will inform the selection of a consumer health dose based on the relative exposure of nature-identical astaxanthin following oral administration of CDX-085. CDX-085 has demonstrated oral bioavailability in multiple animal studies in different species (mice rats dogs monkeys) but has not been tested head-to-head against microalgal astaxanthin. Cardax is targeting product launch in 2016 following GRAS designation.
Cardax believes that the current manufacturing capability of microalgal astaxanthin producers will not satisfy the growing demand for astaxanthin in human health applications and there is a need for synthetic production of bioavailable nature-identical astaxanthin products with high-purity batch-to-batch consistency and reliable large-volume supply at economical costs.
“We look forward to the results of this study” said Cardax CEO David G. Watumull. “It furthers a critical component of our development strategy.”
View original article at: Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin